{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Bliss GVS Pharma Ltd is Rated Hold by MarketsMOJO
Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 25 June 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.
Bliss GVS Pharma Gains 11.07%: 6 Key Factors Driving the Surge
Bliss GVS Pharma Ltd delivered a strong weekly performance from 15 to 19 June 2026, gaining 11.07% to close at Rs.486.60, significantly outperforming the Sensex’s 2.35% rise. The stock demonstrated consistent upward momentum, hitting multiple new 52-week and all-time highs throughout the week amid robust technical indicators and positive financial trends. Despite a minor pullback on the final trading day, Bliss GVS Pharma maintained its bullish trajectory, supported by improved market sentiment and an upgraded rating from MarketsMOJO.
Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 493.7
After a sustained rally of over 15% in just nine trading sessions, Bliss GVS Pharma Ltd surged to a fresh 52-week high of Rs 493.7 on 19 Jun 2026, marking a remarkable ascent from its 52-week low of Rs 118.35. This milestone underscores the stock’s strong price momentum and technical alignment amid a broader market environment that remains subdued.
Bliss GVS Pharma Ltd Hits All-Time High of Rs 488.95 as Momentum Builds Across Timeframes
Bliss GVS Pharma Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone on 19 June 2026 by touching an all-time high price of Rs.488.95. This achievement reflects the company’s sustained performance and strong market momentum over recent periods.
Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 483
From a 52-week low of Rs 118.35 to a fresh peak of Rs 483 on 18 Jun 2026, Bliss GVS Pharma Ltd has surged an impressive 239.78% over the past year, vastly outperforming the Sensex’s decline of 5.14%. This remarkable rally is underpinned by a strong alignment of technical indicators and sustained price momentum, marking a significant milestone for the micro-cap pharmaceutical player.
From Steady Gains to Record Close: Bliss GVS Pharma Ltd Hits All-Time High at Rs 483
Bliss GVS Pharma Ltd has reached a significant milestone, touching its all-time high price of Rs.483 on 18 June 2026. This achievement reflects the company’s sustained performance and robust market presence within the Pharmaceuticals & Biotechnology sector.
Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 472.65
Surging past its previous peaks, Bliss GVS Pharma Ltd reached a new 52-week high of Rs 472.65 on 17 Jun 2026, marking a remarkable rally that has seen the stock appreciate by over 233% in the past year, vastly outperforming the Sensex’s decline of 5.54% over the same period.
Bliss GVS Pharma Ltd Hits All-Time High of Rs 472 as Momentum Builds Across Timeframes
Bliss GVS Pharma Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by touching an all-time high stock price of Rs.472 on 17 June 2026, marking a remarkable phase in its market journey.
Bliss GVS Pharma Ltd is Rated Hold
Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 14 June 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance.
Bliss GVS Pharma Gains 3.12%: 5 Key Factors Driving the Week’s Momentum
Bliss GVS Pharma Ltd recorded a 3.12% gain over the week ending 5 June 2026, closing at Rs.438.05, outperforming the Sensex which declined by 0.78%. The stock demonstrated strong resilience and momentum, hitting multiple new 52-week and all-time highs amid a mixed broader market environment. Key events including an upper circuit surge and robust financial results underpinned the stock’s performance during the week.
Bliss GVS Pharma Ltd is Rated Hold
Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 447.35
From a 52-week low of Rs 118.35 to a new peak of Rs 447.35, Bliss GVS Pharma Ltd has surged an impressive 228.16% over the past year, vastly outperforming the Sensex which declined 8.58% in the same period. This remarkable rally culminated in the stock hitting its all-time high on 3 June 2026, fuelled by a confluence of strong technical signals and sustained price momentum.
From Steady Gains to Record Close: Bliss GVS Pharma Ltd Hits All-Time High at Rs 447.35
Extending its recent rally, Bliss GVS Pharma Ltd touched a fresh all-time high of Rs 447.35 on 3 Jun 2026, marking a significant milestone in its price journey amid a volatile session.
Bliss GVS Pharma Ltd Locks at Upper Circuit With 8.82% Gain — Buyers Queue, Sellers Absent
At Rs 442.65, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bliss GVS Pharma Ltd locked at its upper circuit of 8.82% on 2 Jun 2026, with buyers queuing and no sellers willing to part with shares.
Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 440.15
From a 52-week low of Rs 118.35 to a fresh peak of Rs 440.15 on 2 Jun 2026, Bliss GVS Pharma Ltd has surged an impressive 222.64% over the past year, vastly outperforming the Sensex which declined 8.83% during the same period. This remarkable rally is underpinned by a strong alignment of technical indicators and sustained price momentum, even as the broader market trades near its own lows.
Bliss GVS Pharma Ltd Hits All-Time High of Rs 434.35 as Momentum Accelerates
Bliss GVS Pharma Ltd has reached a significant milestone by touching its all-time high price of Rs 429.35 on 2 June 2026, marking a remarkable achievement for the pharmaceuticals and biotechnology company. This surge reflects the company’s sustained strong performance across multiple financial and technical parameters, underscoring its resilience and growth trajectory in a competitive sector.
Bliss GVS Pharma Surges 41.51%: 7 Key Events Driving the Rally
Bliss GVS Pharma Ltd delivered a remarkable weekly performance, surging 41.51% from Rs.300.20 to Rs.424.80 between 25 and 29 May 2026, vastly outperforming the Sensex’s marginal 0.01% gain. The stock hit multiple new 52-week and all-time highs during the week, driven by strong technical momentum, robust financial results, and heightened market interest amid volatile trading sessions.
Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 412.35
Surging past its previous peaks, Bliss GVS Pharma Ltd reached a new 52-week high of Rs 412.35 on 29 May 2026, marking a remarkable rally of over 206% from its low of Rs 118.35 in the past year. This milestone underscores a sustained momentum driven by a confluence of bullish technical indicators and consistent price appreciation.
Bliss GVS Pharma Ltd Hits All-Time High of Rs 404.45 as Momentum Builds Across Timeframes
Bliss GVS Pharma Ltd has reached a significant milestone by touching an all-time high price of Rs.404.45 on 29 May 2026, reflecting a remarkable upward trajectory in its stock performance within the Pharmaceuticals & Biotechnology sector.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
